Edition:
Deutschland

Chembio Diagnostics Inc (CEMI.OQ)

CEMI.OQ on NASDAQ Stock Exchange Capital Market

3.81USD
22:00 Uhr
Change (% chg)

$-0.22 (-5.46%)
Prev Close
$4.03
Open
$3.75
Day's High
$4.01
Day's Low
$3.70
Volume
788,206
Avg. Vol
446,806
52-wk High
$15.88
52-wk Low
$2.25

About

Chembio Diagnostics, Inc. is a provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. The Company is primarily focused on expanding its product portfolio based upon its Dual Path Platform (DPP). The Company's products include rapid tests for the detection of human immunodeficiency... (more)

Buy/Sell

Sell Hold Buy
3.00 Mean rating from 4 analysts

Overall

Beta: 1.19
Market Cap(Mil.): $77.55
Shares Outstanding(Mil.): 12.31
Dividend: --
Yield (%): --

BRIEF-Chembio Diagnostics Awarded Barda Contract For Development Of DPP Covid-19 Point-Of-Care Antigen System

* CHEMBIO DIAGNOSTICS AWARDED BARDA CONTRACT FOR DEVELOPMENT OF DPP COVID-19 POINT-OF-CARE ANTIGEN SYSTEM

Chembio shares slump as FDA revokes emergency use of COVID-19 test

June 17 Shares of Chembio Diagnostics Inc slumped more than 60% on Wednesday after the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization for its COVID-19 antibody test kit on concerns about its accuracy.

BRIEF-Chembio To Work With FDA Regarding Revoked Clearance For COVID-19 Test

* CHEMBIO DIAGNOSTICS - INTEND TO CONTINUE WORKING WITH FDA WITH RESPECT TO MODIFICATION OF DPP COVID-19 SYSTEM - SEC FILING

BRIEF-FDA Revokes Emergency Use Authorization for Chembio Antibody Test

* FDA SAYS REVOKES EMERGENCY USE AUTHORIZATION FOR CHEMBIO ANTIBODY TEST

BRIEF-Chembio Diagnostics Receives FDA 510(K) Clearance For DPP Zika IgM System

* CHEMBIO DIAGNOSTICS RECEIVES FDA 510(K) CLEARANCE FOR DPP ZIKA IGM SYSTEM Source text for Eikon: Further company coverage:

U.S. RESEARCH ROUNDUP- Capri Holdings, Frequency Therapeutics, Nine Energy Service

May 18 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Capri Holdings, Frequency Therapeutics and Nine Energy Service, on Monday. HIGHLIGHTS * Abercrombie & Fitch Co : JP Morgan raises target price to $12 from $11 * Capri Holdings Ltd : Piper Sandler cuts to neutral from overweight * Frequency Therapeutics Inc : JP Morgan cuts to neutral from overweight * Wayfa

BRIEF-Chembio Diagnostics Announces US Distribution Agreement To Expand Reach Of DPP Covid-19 Serological Test

* CHEMBIO DIAGNOSTICS ANNOUNCES US DISTRIBUTION AGREEMENT TO EXPAND REACH OF DPP COVID-19 SEROLOGICAL TEST WITH THERMO FISHER SCIENTIFIC’S HEALTHCARE CHANNEL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Chembio Diagnostics Announces Proposed Public Offering Of Common Stock

* CHEMBIO DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics Attains CE Marking For Dpp Covid-19 System For Igg And Igm Antibodies

* CHEMBIO DIAGNOSTICS ATTAINS CE MARKING FOR DPP COVID-19 SYSTEM FOR IGG AND IGM ANTIBODIES Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.09%
Rohstoffe -1.34%
Industrie -1.24%
Konjunktur abhängige Waren & Dienstleistungen +0.19%
Konjunktur unabhängige Waren & Dienstleistungen -1.97%
Finanzindustrie -0.83%
Pharma -0.72%
Technologie -0.43%
Telekommunikation -0.60%